WASHINGTON—Allergan Inc., which makes eye care products and Botox anti-wrinkle injections, spent $310,000 lobbying Congress in the last quarter of 2009, according to a disclosure form it filed recently with the House clerk’s office.
The Irvine, Calif., company lobbied on legislation to give the Food and Drug Administration authority to approve generic versions of biotech drugs. Unlike traditional chemical drugs, biotech drugs like Botox have never faced generic competition because the FDA lacks authority to approve cheaper copies. Read the full story at Mercury News
Recent Comments